News | Remote Monitoring | February 17, 2016

Remote Telemonitoring Does Not Reduce Heart Failure Readmissions

While readmissions, mortality do not decrease, researchers see improvements in 180-day quality of life compared to standard care

February 17, 2016 — Increasingly patients and providers are interested in using remote monitoring devices to help with their healthcare. Researchers at the University of California Los Angeles (UCLA) sought to determine if these devices could be useful in preventing 180-day all-cause hospital readmissions for heart failure patients.

They enrolled 1,437 patients from UCLA, UC Davis, UC Irvine, UC San Diego, UC San Francisco and Cedars-Sinai Medical Center in Los Angeles who were randomized into two groups. One group received pre-discharge self-management health coaching along with a Bluetooth-enabled scale, Bluetooth blood pressure/text message device and a transmission pod, and were asked to do daily measurements and answer symptom questions. These measures were checked daily by a centralized nurse call center and if measurements were too high or too low, patients were called to determine what the problem was and if necessary were referred to their healthcare providers or an emergency department. Patients also received scheduled reinforcement of health coaching on a weekly basis for the first month and then monthly through six months. The control group received standard care. The enrollment procedures had very few exclusion criteria in order to mirror potential actual use by health systems, so that patients with a wide range of socioeconomic backgrounds and health comorbidities were enrolled in the study.

The researchers found that combined health coaching and remote monitoring did not reduce all-cause 180-day hospital readmissions among heart failure patients, and did not have significant effects on 30-day hospital readmissions, 30-day mortality or 180-day mortality. These findings were previously reported at the American Heart Association (AHA) scientific meeting on Nov. 8, 2015.

This study additionally reported on quality of life findings not presented at the AHA meeting. The researchers found that intervention patients reported significantly improved quality of life at 180 days when compared to usual care patients based on the Minnesota Living with Heart Failure questionnaire, a well-validated instrument for measuring quality of life among heart failure patients.

The authors concluded that the use of remote monitoring technology is not yet ready for widespread adoption for the purposes of reducing readmissions. A major issue requiring further research is who can adhere to using these technologies and how to improve adherence. Also, further research is needed to evaluate quality of life benefits.

Michael Ong, M.D., Ph.D., associate professor-in-residence of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA, is the study’s lead investigator.

Results were published in the Feb. 8 issue of JAMA Internal Medicine.

For more information: www.archinte.jamanetwork.com/journal


Related Content

News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
Subscribe Now